Screener
Globus Medical GMED Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Globus Medical in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Globus Medical’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054450
FAQ
- What is Globus Medical's cash & equivalents?
- Globus Medical (GMED) reported cash & equivalents of $507.75M in Q2 2026.
- How has Globus Medical's cash & equivalents changed year-over-year?
- Globus Medical's cash & equivalents increased by 121.3% year-over-year, from $229.45M to $507.75M.
- What is the long-term trend for Globus Medical's cash & equivalents?
- Over 5 years (2020 to 2025), Globus Medical's cash & equivalents has grown at a 17.1% compound annual growth rate (CAGR), from $239.4M to $526.16M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Globus Medical's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude